Navigation Links
FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Date:3/17/2008

FDA Clearance Validates Platform Designed to Deliver Electronic X-ray-Based Therapy Directly to Cancer Sites in Minimally Shielded Clinical Settings

SUNNYVALE, Calif., March 17 /PRNewswire/ -- Xoft, Inc., today announced that it has received expanded clearance from the U.S. Food & Drug Administration (FDA) for the Axxent(R) Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated.

As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.

"The prospect of expanding the use of Electronic Brachytherapy beyond our breast cancer patients is very exciting," said Adam Dickler, radiation oncologist at Little Company of Mary Hospital in Chicago. "The ability to deliver electronic X-ray based therapy directly to the cancer site spares healthy tissue and gives us the ability to provide that therapy in a broader spectrum of clinical settings. This tool has been very well received by our breast cancer patients and we would expect it deliver similar benefits across a range of cancer treatments."

Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in virtually any clinical setting under the supervision of a radiation oncologist. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded envir
'/>"/>

SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. New filter clears up fiber optic communications
2. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
8. HOYA ConBio and The Hornbrook Group Announce Expanded Alliance
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
11. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...NGTON, Minn., Nov. 30 Acuo Technol...e management software, data migration tools and se...spitals and Clinics for a new Vendor Neutral Archi...e across the Allina network of hospitals, clinics ...sed on the Acuo Technologies DICOM Services Grid(T...
(Date:11/30/2009)..., Nov. 30 Dr. Jessica Torrente, As...n University Medical Center in Washington, D.C., d...ific Gamma Imaging (BSGI) in clinical practice as ...reast cancer today at the annual meeting of the Ra..."The purpose of the exhibit was to demonstrate how...
(Date:11/30/2009)...SEATTLE, Nov. 30 Cell Th...unced today that its new class of platinum-based a...trated a stronger anti-tumor potency and activity ...pounds as well as the ability to overcome cisplati...re presented in a paper titled "Novel Bis-platinum...
(Date:11/29/2009)... available in German . , The concept of con...sics. The most famous example is that of quarks wh...w Prof. Bella Lake from Helmholtz-Zentrum Berlin t...eport for the first time an experimental realizati...in a condensed matter system. , The concept of c...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Spinons -- confined like quarks 2
...s most widely used drugs, is also one of the trick...t risk of serious problems when given the standard...rations of "personalized medicine" based on geneti...created a model to help doctors determine the best... , Three University of Wisconsin-Madison researc...
...N, Mass., Feb. 18 Psychemedics Corporation (Nasda...-end financial results for the period ended Decemb...ly dividend of $0.17 per share payable to sharehol...arch 20, 2009. This will be the Company,s 50th co...evenue for the year ended December 31, 2008 was $2...
...ary 18 ,Amsterdam Molecular Therapeutics (Euronext...y, announced today that it will release its financ...ruary 24, 2009 at 7:00 am,Central European Time (C...nduct a conference call that day at 3 p.m. CET. , ...-949-4166 (toll free). The,number for Germany is 0...
Other Biology Technology:Genetic information personalizes warfarin prescribing 2Genetic information personalizes warfarin prescribing 3Psychemedics Corporation Announces 2008 Year End Results 2Psychemedics Corporation Announces 2008 Year End Results 3Psychemedics Corporation Announces 2008 Year End Results 4Psychemedics Corporation Announces 2008 Year End Results 5AMT to Release Full Year 2008 Results on February 24, 2009 2
(Date:11/30/2009)...ght the stress of seeing your extended family over...w research report in the December 2009 print issue...w.jleukbio.org ) shows that you might be right. He...ght lead to entirely new treatments that help keep...zema under control. That,s because researchers fro...
(Date:11/26/2009)...s are some of the Ocean,s most distinctive residen...is strange head shape, says Michelle McComb from ...s the shark,s vision. ,Perhaps their visual field ... McComb, giving the sharks excellent stereovision ..., there were two schools of thought on this theory...
(Date:11/26/2009)... (November 26, 2009) Whitehead researchers have d...lls to pinpoint specific genes and proteins used b.... , In most human cell cultures genes are presen... one from the mother. Gene inactivation by mutatio...s inactivated, the second copy usually remains act...
Breaking Biology News(10 mins):Seeing family for the holidays? Scientists discover how the stress might kill you 2Wide heads give hammerheads exceptional stereo view 2Knockouts in human cells point to pathogenic targets 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 1New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 6Perception May Affect Drinking by College Students 52095 1Perception May Affect Drinking by College Students 52095 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 1Exposure to Common Pollutant in Womb Might Lower IQ 52093 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 3
...e can be increased by eating a higher protein diet... journal Cell Metabolism, published by Cell Press....er found by the researchers to reduce food intake ...when given by injection. , "We,ve now found that ...s the body,s own PYY, helping to reduce hunger and...
...r, healthier lives since the development of highly... In fact, most patients on the drug regimen do so ...cells appear to return to pre-HIV levels. But two ...ron Diamond AIDS Research Center (ADARC) show that...rebound, suggesting the need for additional ways t...
... that vaccinating mice with embryonic stem cells p... cancer cells transplanted into them after the vac...g chemicals. , The findings suggest that it coul...nes that prevent cancers in humans, such as heredi...d by smoking or other environmental factors. ,...
Other Biology News:Eating protein boosts hormone that staves off hunger 2HIV-1 kills immune cells in the gut that may never bounce back 2HIV-1 kills immune cells in the gut that may never bounce back 3Vaccination with embryonic stem cells prevents lung cancer in mice 2Vaccination with embryonic stem cells prevents lung cancer in mice 3
Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: